Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "dexamethasone failed to demonstrate any protective advantage in terms of mitigating short-term PMCs or infectious complications, or to confer any long-term survival benefit." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.